Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Sapanisertib + Telaglenastat for Lung Cancer
Recruiting1 awardPhase 1
New York, New York
This trial is studying the side effects and best dose of two drugs, CB-839 HCl and sapanisertib, when given together to treat patients with non-small cell lung cancer that has spread to other places in the body.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service